Full Press Release Details
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
| Thursday, March 5th@ 8:30am ET | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializingDefenCath®(taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, includingMINOCIN®(minocycline) for Injection,REZZAYO®(rezafungin for injection), VABOMERE®(meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA®(delafloxacin), andKIMYRSA®(oritavancin), as well asTOPROL-XL®(metoprolol succinate).
CorMedix has ongoing clinical studies forDefenCathin Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to developDefenCathas a catheter lock solution for use in other patient populations.REZZAYOis currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit:www.cormedix.comorwww.melinta.com.